Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Start-Up Quarterly Statistics: Fundraising Fell, But Deal-Making Rose In Q3

Executive Summary

A review of biopharma start-up deal-making and financing activity from July through September 2017, based on data from Strategic Transactions, showed that fundraising declined 18% from the previous quarter, however the number of acquisitions doubled to eight.

You may also be interested in...



Spark's Gene Therapy Is On The Cusp Of Approval; Now It Gets Interesting

Spark's Luxturna is all but guaranteed to reach the US market as the first gene therapy following a unanimous positive FDA advisory committee review. Discussions about cost and value are sure to intensify.

Tech Transfer Roundup: Neon Licenses NKI IP To Advance Cell Therapy Into Clinic

Continuing a partnership between Neon co-founder and two Netherlands Cancer Institute researchers, agreement will help autologous T-cell candidate move into Phase I. Plus Scrip's monthly roundup of tech transfer deals.

Deal Watch: Celgene The Latest To Buy Into Nimbus’ Computational Chemistry Approach

The big biotech takes options on preclinical Tyk2 and STING programs. REGENXBIO drops out of the bidding for Dimension, ceding to Ultragenyx, and Eisai licenses four drugs to Uruguay’s Grupo Biotoscana.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1122113

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel